The Pains of Opioid Prescribing

The United States is in a state of emergency: The Centers for Disease Control and Prevention (CDC) estimates that 91 Americans die each day from an opioid overdose.1 Over the past two decades, the...

Online Exclusives

European Commission Approves Obinutuzumab Combination Treatment for FL

The European Commission approved obinutuzumab in combination with chemotherapy as firstline treatment for patients with previously untreated, advanced follicular lymphoma (FL), followed by obinutuzumab...

Maryland Enacts First Price-Gouging Law for Pharmaceutical Companies

By denying an injunction filed by a generic-drug industry trade group, a U.S. District Court allowed Maryland to implement the first law penalizing drug...

News

From the Blood Journals

WIB_icon

Examining Ibrutinib as Secondline Therapy for Chronic Graft-Versus-Host Disease

On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved the Bruton tyrosine kinase inhibitor ibrutinib as a secondline treatment for adult...
WIB_icon

Fertility Issues in Patients With Inherited Bone Marrow Failure Syndromes

More patients with inherited bone marrow failure syndromes (IBMFS) are surviving to adulthood. As they do, they face barriers to pregnancy. It is still...

Multimedia

Pulling Back the Curtain: Brian G. M. Durie, MD

In more from our interview with Dr. Durie, hear more about how interactions with his father’s doctor piqued Dr. Durie’s interest in medicine, and...

pASHions: B.Y.O.B. (Build Your Own Boat) With Joseph H. Antin, MD

In more from our interview with Dr. Antin, he offers two simple rules for starting a new hobby with your spouse, and discusses the...

Pulling Back the Curtain: Gerald A. Soff, MD

Hear more from our interview with Dr. Soff, where he shares more about his career in hematology, his myeloma diagnosis, and why Sergio Giralt, MD, is...
video

Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an "impressive" response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr....

On Location

Emicizumab Significantly Decreases Bleeding Rate, Compared With No Treatment in Patients With Hemophilia A

In the phase III HAVEN-1 study, preventive treatment with emicizumab significantly reduced bleeding rates, compared...

RNA Interference Therapy Fitusiran Improves Thrombin Generation in Patients With Hemophilia

The investigational RNA interference therapy fitusiran lowered levels of antithrombin in patients with hemophilia A...

Is Anticoagulant Therapy to Prevent Recurrent VTE Worth the Bleeding Risk in Older Patients With Cancer?

Though anticoagulants are common frontline treatment for patients with venous thromboembolism (VTE), patients with cancer...

Phase II Results Show Activity of Polatuzumab Vedotin Combination in DLBCL

The CD79b-targeting antibody drug conjugate polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone...

Evaluating HCT Outcomes in Patients With Beta-Thalassemia

Hematopoietic cell transplantation (HCT) is associated with a disease-free survival rate of 90 percent at...

Fourth Drug’s the Charm? Comparing Combination Therapies in the Myeloma XI Trial

Triplet combinations of anti-myeloma induction therapies lead to deeper, longer remissions than doublet combinations. Results...

Latest Headlines

Advertisement

ASH Directions

ASH Selects Hematologists for 2017 Visitor Training Program, New MIPS Reporting Tool Available, and...

ASH Selects Hematologists from Developing Countries to Participate in Training Program The American Society of Hematology (ASH) selected 25 hematologists and medical professionals from developing...

2017 ASH Clinical Research Training Institute Participants, AML Matters Summit, and more

Fellows and Junior Faculty Selected for 2017 ASH Clinical Research Training Institute Twenty hematology and hematology/oncology fellows and junior faculty will participate in the 2017...

Sign up for our e-Newsletter!

UC San Diego Researchers Receive Grant for CAR T-cell Therapy, New President at Seidman...

Theodoros N. Teknos Appointed President and Scientific Officer of University Hospitals Seidman Cancer Center Theodoros N. Teknos, MD, has been named the president and scientific...

New CDC Director Named, NIH Awards Grants for Cancer Cell Metastases, and more

Brenda Fitzgerald Named New Director of the Centers for Disease Control and Prevention Brenda Fitzgerald, MD, the Georgia Public Health Commissioner, has been appointed director...

Ned Sharpless Named New NCI Director, 2017 Pew-Stewart Cancer Research Scholars Announced, and more

Norman Sharpless Named Director of the National Cancer Institute Norman “Ned” Sharpless, MD, has been appointed director of the National Cancer Institute (NCI) by President...

The Pains of Opioid Prescribing

The United States is in a state of emergency: The Centers for Disease Control and Prevention (CDC) estimates that 91 Americans die each day...

The Rank Tank

Are public health-care ratings an indicator of quality or of popularity? Each summer, U.S. News & World Report releases its list of the best hospitals...

Mining the “Gold Rush” of Immunotherapy Clinical Trials

Immunotherapy has the potential to revolutionize cancer treatment, but as the number of immunotherapy clinical trials continues to grow, so do the challenges and...